Products - Brain cancers | Topic | NICE

Showing 5 products

Date | Title

Product type: GuidanceRemove ‘Product type: Guidance’ filter
New and updated: New in the last 6 monthsRemove ‘New and updated: New in the last 6 months’ filter

Asunercept for treating glioblastoma [ID1301]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
LAM-561 with radiotherapy and temozolomide for treating IDH1 wild-type glioblastoma [ID4022]
Status:
Awaiting development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Suspected Cancer: recognition and referral (update)
Status:
In development
Programme:
NICE guideline
Expected publication date:
25 March 2026
Tovorafenib for treating relapsed or refractory paediatric low-grade glioma with BRAF fusion or rearrangement or BRAF V600 mutation in people 6 months and over ID6557
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
TBC
Vorasidenib for treating astrocytoma or oligodendroglioma with IDH1 or IDH2 mutations after surgery in people 12 years and over [ID6407]
Status:
In development
Programme:
Technology appraisal guidance
Expected publication date:
29 April 2026